Article
Estimating quality adjusted progression free survival of first-line treatments for EGFR mutation positive non small cell lung cancer patients in The Netherlands.
Health and quality of life outcomes - 10 Sept 2012
Verduyn S Cora, Biesma Bonne, Schramel Franz M N H, van der Scheer Feike W, Langenfeld Merel K, de Peuter Maria A, Dingemans Anne-Marie C
Abstract excerpt
BACKGROUND: Gefitinib, a tyrosine kinase inhibitor, is an effective treatment in advanced non-small cell lung cancer (NSCLC) patients with an activating mutation in the epidermal growth factor receptor (EGFR). Randomised clinical trials showed a benefit in progression free survival for gefitinib versus doublet chemotherapy regimens in patients with an activated EGFR mutation (EGFR M+). From a patient perspective,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.